by barry101 | Sep 8, 2022 | Press Releases
HOUSTON, Sept. 8, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today...
by barry101 | Sep 7, 2022 | Press Releases
HOUSTON, Sept. 7, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today...
by barry101 | Sep 6, 2022 | Press Releases
– Glioblastoma is the most aggressive malignant primary brain tumor with serious unmet medical need HOUSTON, Sept. 6, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical...
by barry101 | Aug 19, 2022 | Press Releases
– Preliminary results of third cohort in the first-in-human Phase 1a allows Company to proceed to next single ascending dose (SAD) of 64 mg/kg dose and the first multiple ascending dose (MAD) cohort to commence with 32 mg/kg dose of WP1122 – HOUSTON, Aug....
by barry101 | Aug 15, 2022 | Press Releases
– Continued advancement across clinical and preclinical programs; on track with multiple milestones and key data readouts expected through the second half of 2022 – Company has sufficient capital to fund operations beyond mid-2024 HOUSTON, Aug. 15, 2022...
by barry101 | Jul 28, 2022 | Press Releases
– Preliminary Phase 1b data demonstrated clinical activity, defined as stable disease or better – Company determines RP2D to be 360 mg/m2 and will begin Phase 2 recruitment – Annamycin has Fast Track Status and Orphan Drug Designation from FDA for...
